The HDAC2 Knockout HT29 Polyclonal Cells product consists of a population of HT29 human colon adenocarcinoma cells that have undergone CRISPR/Cas9-mediated disruption of the HDAC2 gene, generating a heterogeneous polyclonal knockout model with loss-of-function of histone deacetylase 2. This gene-edited cell population provides a physiologically relevant platform for investigating HDAC2-dependent epigenetic regulation, transcriptional repression, and signaling pathway crosstalk in a colorectal cancer context.
The HT29 cell line is an epithelial model established from a primary colorectal adenocarcinoma, widely utilized in gastrointestinal cancer research. It harbors inactivating mutations in the TP53 and APC tumor suppressor genes, mirroring common genetic aberrations observed in sporadic colorectal tumors. The epithelial morphology and adherent growth characteristics of HT29 cells facilitate a broad range of in vitro assays, making this knockout derivative especially suitable for functional studies of chromatin-modifying enzymes and their role in oncogenesis.
HDAC2 operates as a transcriptional corepressor through its catalytic removal of acetyl groups from lysine residues on histones H3 and H4, promoting chromatin condensation and gene silencing. It is recruited to target promoters by corepressor complexes including SIN3A, NuRD (comprising MTA1 and MBD2), CoREST, and NCoR/SMRT. In addition to histones, HDAC2 deacetylates key non-histone proteins such as p53, E2F1, YY1, BCL6, and STAT3, thereby modulating their transcriptional activities. Upstream regulation involves the SP1 transcription factor, CK2 kinase-mediated phosphorylation, and activation by IL-6/STAT3 signaling. Downstream, HDAC2-mediated deacetylation suppresses the expression of the cyclin-dependent kinase inhibitor CDKN1A (p21WAF1/CIP1), promoting cell cycle progression. The enzyme also interfaces with Notch, Wnt/??-catenin, and p53 signaling networks, positioning it as a critical node in growth control.
In the HT29 colorectal adenocarcinoma milieu, ablation of HDAC2 is expected to derepress tumor suppressor genes such as CDKN1A, leading to reduced proliferation and heightened apoptotic sensitivity. Given the already compromised TP53 and APC pathways, this knockout model enables the study of p53-independent epigenetic mechanisms and Wnt cascade modulation. It provides a valuable tool for evaluating the selectivity and potency of HDAC inhibitors, including vorinostat and romidepsin, in cells with impaired tumor suppressor axes. Moreover, the polyclonal nature of the knockout population better reflects heterogeneous tumor cell responses compared to clonal lines.
Researchers can utilize these cells in diverse experimental workflows, including Western blot validation of HDAC2 knockout and global histone acetylation changes, RT-qPCR quantification of CDKN1A and other target genes, and ChIP-qPCR analysis of promoter-specific histone acetylation marks. Proliferation can be assessed via MTT or BrdU assays, apoptosis by Annexin V staining, and cell cycle distribution by flow cytometry. The model is also suited for RNA-seq transcriptomic profiling to map HDAC2-dependent gene networks and for high-throughput drug sensitivity screens. For technical inquiries or customized support, please contact Ascent Research.
